Google Life Sciences and Sanofi have joined hands to take on the menace of diabetes and to improve care and outcomes of people suffering from the disease.
Google will be bringing in its expertise in analytics, miniaturised electronics and low power chip design to the table while Sanofi will be extended its expertise in diabetes treatments to come up with ways to improve care and outcomes for patients suffering from type 1 and type 2 diabetes.
Through the collaboration the two companies are looking to develop new tools that bring together many of the previously siloed pieces of diabetes management and enable new kinds of interventions including health indicators such as blood glucose and hemoglobin A1c levels, patient-reported information, medication regimens and sensor devices.
The two companies intend to provides means through which patients will be able to successfully manage their diabetes, which would reduce the risk of complications, improve outcomes and ultimately lower costs.
“As a global leader in diabetes care, we have both an obligation and a commitment to provide integrated solutions for people living with diabetes,” said Olivier Brandicourt, MD, Chief Executive Officer, Sanofi. “This initiative combines Sanofi’s strength and knowledge in diabetes with Google’s leadership in technology and analytics to create a first-of-its-kind initiative with the potential to transform diabetes care.”
“With new technologies emerging to provide a more continuous and real-time view of a patient’s health, we can see the promise for more proactive and effective ways to control diabetes,” said Andy Conrad, CEO of the life sciences team at Google. “Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life.”
